skip to main content
US FlagAn official website of the United States government
dot gov icon
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
https lock icon
Secure .gov websites use HTTPS
A lock ( lock ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.


This content will become publicly available on April 9, 2026

Title: Natural sulfur compounds in mental health and neurological disorders: insights from observational and intervention studies
Over the years, the global disease burden of neurological disorders (NDs) and mental disorders (MDs) has significantly increased, making them one of the most critical concerns and challenges to human health. In pursuit of novel therapies against MD and ND, there has been a growing focus on nutrition and health. Dietary sulfur, primarily derived from various natural sources, plays a crucial role in numerous physiological processes, including brain function. This review offers an overview of the chemical composition of several natural sources of the sulfur-rich substances such as isothiocyanates, sulforaphane, glutathione, taurine, sulfated polysaccharides, allyl sulfides, and sulfur-containing amino acids, all of which have neuroprotective properties. A multitude of studies have documented that consuming foods that are high in sulfur enhances brain function by improving cognitive parameters and reduces the severity of neuropathology by exhibiting antioxidant and anti-inflammatory properties at the molecular level. In addition, the growing role of natural sulfur compounds in repairing endothelial dysfunction, compromising blood–brain barrier and improving cerebral blood flow, are documented here. Furthermore, this review covers the encouraging results of supplementing sulfur-rich diets in many animal models and clinical investigations, along with their molecular targets in MD, such as schizophrenia, depression, anxiety, bipolar disorder, and autism spectrum disorder, and ND, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), and Multiple Sclerosis (MS). The prospects of natural sulfur compounds show great promise as they have potential applications in nutraceuticals, medicines, and functional foods to enhance brain function and prevent diseases. However, additional research is required to clarify the mechanisms by which it works, enhance its bioavailability, and evaluate its long-term safety for broad use.  more » « less
Award ID(s):
1928792
PAR ID:
10596119
Author(s) / Creator(s):
; ; ; ;
Editor(s):
Mosca, Luciana
Publisher / Repository:
Frontiers
Date Published:
Journal Name:
Frontiers in Nutrition
Volume:
12
ISSN:
2296-861X
Format(s):
Medium: X
Sponsoring Org:
National Science Foundation
More Like this
  1. Tuberous Sclerosis (TS) is a rare genetic disorder manifesting with multiple benign tumors impacting the function of vital organs. In TS patients, dominant negative mutations in TSC1 or TSC2 increase mTORC1 activity. Increased mTORC1 activity drives tumor formation, but also severely impacts central nervous system function, resulting in infantile seizures, intractable epilepsy, and TS-associated neuropsychiatric disorders, including autism, attention deficits, intellectual disability, and mood disorders. More recently, TS has also been linked with frontotemporal dementia. In addition to TS, accumulating evidence implicates increased mTORC1 activity in the pathology of other neurodevelopmental and neurodegenerative disorders. Thus, TS provides a unique disease model to address whether developmental neural circuit abnormalities promote age-related neurodegeneration, while also providing insight into the therapeutic potential of mTORC1 inhibitors for both developing and degenerating neural circuits. In the following review, we explore the ability of both mouse and human brain organoid models to capture TS pathology, elucidate disease mechanisms, and shed light on how neurodevelopmental alterations may later contribute to age-related neurodegeneration. 
    more » « less
  2. Halogenated organic compounds are pervasive in natural and built environments. Despite restrictions on the production of many of these compounds in most parts of the world through the Stockholm Convention on Persistent Organic Pollutants (POPs), many “legacy” compounds, including polychlorinated biphenyls (PCBs), are routinely detected in human tissues where they continue to pose significant health risks to highly exposed and susceptible populations. A major concern is developmental neurotoxicity, although impacts on neurodegenerative outcomes have also been noted. Here, we review human studies of prenatal and adult exposures to PCBs and describe the state of knowledge regarding outcomes across domains related to cognition (e.g., IQ, language, memory, learning), attention, behavioral regulation and executive function, and social behavior, including traits related to attention-deficit hyperactivity disorder (ADHD) and autism spectrum disorders (ASD). We also review current understanding of molecular mechanisms underpinning these associations, with a focus on dopaminergic neurotransmission, thyroid hormone disruption, calcium dyshomeostasis, and oxidative stress. Finally, we briefly consider contemporary sources of organohalogens that may pose human health risks via mechanisms of neurotoxicity common to those ascribed to PCBs. 
    more » « less
  3. Abstract A major obstacle facing brain diseases such as Alzheimer's disease, multiple sclerosis, brain tumors, and strokes is the blood–brain barrier (BBB). The BBB prevents the passage of certain molecules and pathogens from the circulatory system into the brain. Therefore, it is nearly impossible for therapeutic drugs to target the diseased cells without the assistance of carriers. Nanotechnology is an area of growing public interest; nanocarriers, such as polymer‐based, lipid‐based, and inorganic‐based nanoparticles can be engineered in different sizes, shapes, and surface charges, and they can be modified with functional groups to enhance their penetration and targeting capabilities. Hence, understanding the interaction between nanomaterials and the BBB is crucial. In this Review, the components and properties of the BBB are revisited and the types of nanocarriers that are most commonly used for brain drug delivery are discussed. The properties of the nanocarriers and the factors that affect drug delivery across the BBB are elaborated upon in this review. Additionally, the most recent developments of nanoformulations and nonconventional drug delivery strategies are highlighted. Finally, challenges and considerations for the development of brain targeting nanomedicines are discussed. The overall objective is to broaden the understanding of the design and to develop nanomedicines for the treatment of brain diseases. 
    more » « less
  4. Epilepsy is a disease caused by abnormal brain activity due to disturbed nerve cell activity. It is the fourth most common neurological disorder. Only about 7 out of 10 individuals with epilepsy are successfully treated using anti-epileptic drugs. In the pharmaceutical industry, there has been a growing demand for cannabinoids from Cannabis sativa, commonly known as marijuana, for therapeutic, clinical, and nutraceutical supplements. More recently, the legalization of marijuana for clinical research has allowed to further explore the efficacy in the treatment of several neurological disorders like epilepsy. Unlike opioids, cannabinoids are not psychoactive, making it a potentially more favorable therapeutic drug. Most studies showing the efficacy of Cannabis as a treatment strategy point to the pain management associated with the binding of endocannabinoid G coupled protein receptors CB1 and CB2. Though there are cannabinoid therapeutic drugs like Epidiolex approved by the Food and Drug Administration (FDA), plant-based natural compounds are safer, and effective with no side effects. 
    more » « less
  5. Tremendous recent literature show that associations between different brain regions, i.e., brain connectivity, provide early symptoms of neurological disorders. Despite significant efforts made for graph neural network (GNN) techniques, their focus on graph nodes makes the state-of-the-art GNN methods not suitable for classifying brain connectivity as graphs where the objective is to characterize disease-relevant network dysfunction patterns on graph links. To address this issue, we propose Multi-resolution Edge Network (MENET) to detect disease-specific connectomic benchmarks with high discrimination power across diagnostic categories. The core of MENET is a novel graph edge-wise transform that we propose, which allows us to capture multi-resolution “connectomic” features. Using a rich set of the connectomic features, we devise a graph learning framework to jointly select discriminative edges and assign diagnostic labels for graphs. Experiments on two real datasets show that MENET accurately predicts diagnostic labels and identify brain connectivities highly associated with neurological disorders such as Alzheimer’s Disease and Attention-Deficit/Hyperactivity Disorder. 
    more » « less